Juno Therapeutics (JUNO) Receives Media Sentiment Score of 0.16

Media stories about Juno Therapeutics (NASDAQ:JUNO) have been trending somewhat positive recently, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Juno Therapeutics earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.7328545563286 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news headlines that may have effected Accern Sentiment’s rankings:

How to Become a New Pot Stock Millionaire

Shares of JUNO remained flat at $$86.96 during mid-day trading on Friday. The stock had a trading volume of 2 shares, compared to its average volume of 5,484,542. Juno Therapeutics has a 52 week low of $19.62 and a 52 week high of $87.01. The company has a quick ratio of 4.77, a current ratio of 3.61 and a debt-to-equity ratio of 0.01.

JUNO has been the subject of a number of analyst reports. Wells Fargo downgraded Juno Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, December 12th. Raymond James Financial restated a “buy” rating on shares of Juno Therapeutics in a research note on Monday, December 11th. Maxim Group set a $56.00 price target on Juno Therapeutics and gave the company a “buy” rating in a research note on Wednesday, December 13th. Citigroup downgraded Juno Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, January 17th. Finally, Wedbush downgraded Juno Therapeutics from an “outperform” rating to a “neutral” rating in a research note on Wednesday, January 17th. One research analyst has rated the stock with a sell rating, eighteen have given a hold rating and two have given a buy rating to the company’s stock. Juno Therapeutics currently has a consensus rating of “Hold” and an average price target of $52.55.

In other news, CEO Hans Edgar Bishop sold 270,250 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $46.17, for a total value of $12,477,442.50. Following the completion of the sale, the chief executive officer now directly owns 2,772,679 shares of the company’s stock, valued at $128,014,589.43. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Robert Azelby sold 29,131 shares of Juno Therapeutics stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $68.61, for a total value of $1,998,677.91. Following the sale, the executive vice president now directly owns 73,330 shares of the company’s stock, valued at $5,031,171.30. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 426,465 shares of company stock valued at $24,946,548. Insiders own 15.08% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3339397/juno-therapeutics-juno-receives-media-sentiment-score-of-0-16.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Insider Buying and Selling by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Capital One Financial Weighs in on Cousins Properties’ Q3 2018 Earnings
Capital One Financial Weighs in on Cousins Properties’ Q3 2018 Earnings
Royal Gold  Forecasted to Post Q3 2018 Earnings of $0.42 Per Share
Royal Gold Forecasted to Post Q3 2018 Earnings of $0.42 Per Share
Campbell Soup  Forecasted to Post Q3 2018 Earnings of $0.60 Per Share
Campbell Soup Forecasted to Post Q3 2018 Earnings of $0.60 Per Share
Infineon Technologies  PT Set at €28.00 by Goldman Sachs
Infineon Technologies PT Set at €28.00 by Goldman Sachs
Hauck & Aufhaeuser Reiterates €16.50 Price Target for Hamburger Hafen und Logistik
Hauck & Aufhaeuser Reiterates €16.50 Price Target for Hamburger Hafen und Logistik
Drägerwerk  Earns “Neutral” Rating from Deutsche Bank
Drägerwerk Earns “Neutral” Rating from Deutsche Bank


Leave a Reply

© 2006-2018 Ticker Report. Google+.